Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

INSM - Insmed Incorporated Последние новости | Finranks

Home

/

INSM

I

Insmed Incorporated (INSM)

NMS – Цена в реальном времени. Валюта: USD

132.49

-0.08 (-0.06%)

Рынок открыт: Aug 12, 2026, 3:24 PM EDT

132.01

-0.56 (-0.42%)

Предыдущая сессия: Aug 11, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review

American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review

U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Key contributors include Rocket Lab, ARM Holdings, and Bloom Energy. Key Detractors include Advanced Micro Devices, Netflix, and Alnylam Pharmaceuticals.

Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake

Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake

INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.

Insmed Q2 Earnings Call Highlights

Insmed Q2 Earnings Call Highlights

Insmed NASDAQ: INSM reported second-quarter 2026 revenue growth driven by the continued launch of BRINSUPRI and steady sales of ARIKAYCE, while raising its full-year BRINSUPRI revenue outlook and increasing its long-term peak-sales estimates for its leading products.

Artisan Global Discovery Fund Q2 2026 Portfolio Activity

Artisan Global Discovery Fund Q2 2026 Portfolio Activity

During the quarter, we initiated new positions in Entegris, Cellebrite and C.H. Robinson. In addition to Lattice Semiconductor and Babcock, we added to Games Workshop Group, Tradeweb Markets and Teledyne Technologies during the quarter. In addition to ROBLOX, we ended our investment campaigns in Colliers International and MongoDB.

Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript

Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript

Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript

Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say

Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $1.7 per share a year ago.

Видео

No Data

There is no data to display

Пресс-релизы

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

—Total Company Revenues of $425.5 Million for the Second Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Quarter of 2026— —ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $116.3 Million for the Second Quarter of 2026, Reflecting 8% Growth Over the Second Quarter of 2025— —Company Raises 2026 BRINSUPRI Revenue Guidance to $1.25 Billion to $1.40 Billion— —Company Reiterates 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million— —Company Raises Peak Revenue Estimate for its Three Lead Programs to More than $14 Billion Total— —Peak Revenue Estimate Consists of More than $7 Billion for BRINSUPRI, More than $6 Billion for TPIP, and More than $1 Billion for ARIKAYCE— BRIDGEWATER, N.J., Aug. 6, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.